UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
APRIL 7, 2010
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
|
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|
Yes [ ] |
No [X] |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________
Company Announcement
6 April 2010
Novo Nordisk A/S – Share repurchase programme
On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.
Since the announcement as of 29 March 2010, the following transactions have been made under the programme:
|
|
Number of shares |
Average purchase price |
Transaction value, DKK |
|
Accumulated, last announcement |
3,490,000 |
|
1,392,214,238 |
|
29 March 2010 |
75,000 |
431.0200 |
32,326,500 |
|
30 March 2010 |
75,000 |
430.2200 |
32,266,500 |
|
31 March 2010 |
70,000 |
427.8600 |
29,950,200 |
|
Accumulated under the programme |
3,710,000 |
|
1,486,757,438 |
With the transactions stated above, Novo Nordisk owns a total of 33,981,298 treasury shares, corresponding to 5.5% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.
|
Company Announcement no 18 / 2010 |
Page 1 of 2 | |||
|
|
||||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 Telefax: +45 4444 6626 |
Internet: novonordisk.com |
CVR no: 24256790 |
Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
|
Further information: |
|
|
|
|
|
Media: |
Investors: |
|
|
|
|
Elin K Hansen Tel: (+45) 4442 3450 ekh@novonordisk.com |
Klaus Bülow Davidsen Tel: (+45) 4442 3176 klda@novonordisk.com |
|
|
|
|
|
Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 krop@novonordisk.com |
|
|
|
|
In North America: Sean Clements Tel: (+1) 609 514 8316 secl@novonordisk.com |
In North America: Hans Rommer Tel: (+1) 609 919 7937 hrmm@novonordisk.com |
|
Company Announcement no 18 / 2010 |
Page 2 of 2 | |||
|
|
||||
|
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 Telefax: +45 4444 6626 |
Internet: novonordisk.com |
CVR no: 24256790 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
|
Date: APRIL 7, 2010 |
NOVO NORDISK A/S Lars Rebien Sørensen, President and Chief Executive Officer |